HCW Biologics, WY Biotech Sign License Deal for Immunotherapeutic Product Candidate

MT Newswires Live11-18

HCW Biologics (HCWB) and WY Biotech said Monday they struck a license deal to develop and commercialize one of the former's immunotherapeutic product candidates.

Under the terms, HCW Biologics will receive a $7 million upfront payment from WY Biotech, while the latter will cover all expenses regarding research and development, manufacturing, clinical development, regulatory approval, and commercialization of the candidate, the companies added.

HCW Biologics will cover costs for clinical development, regulatory approval, and commercialization of the candidate in the US, Canada, Central America, and Latin America, the parties said.

HCW Biologics shares surged 246% in recent Monday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484362201?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-18 21:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484362201","market":"us","top_or_hot":-1,"title":"HCW Biologics, WY Biotech Sign License Deal for Immunotherapeutic Product Candidate","media":"MT Newswires Live","content":"<html><body><p> HCW Biologics (HCWB) and WY Biotech said Monday they struck a license deal to develop and commercialize one of the former's immunotherapeutic product candidates.</p><p>Under the terms, HCW Biologics will receive a $7 million upfront payment from WY Biotech, while the latter will cover all expenses regarding research and development, manufacturing, clinical development, regulatory approval, and commercialization of the candidate, the companies added.</p><p>HCW Biologics will cover costs for clinical development, regulatory approval, and commercialization of the candidate in the US, Canada, Central America, and Latin America, the parties said.</p><p>HCW Biologics shares surged 246% in recent Monday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HCW Biologics, WY Biotech Sign License Deal for Immunotherapeutic Product Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHCW Biologics, WY Biotech Sign License Deal for Immunotherapeutic Product Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-18 21:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>HCW Biologics (HCWB) and WY Biotech said Monday they struck a license deal to develop and commercialize one of the former's immunotherapeutic product candidates.Under the terms, HCW Biologics will ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2484362201","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484362201","pubTimestamp":1731935678,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"HCW Biologics  and WY Biotech said Monday they struck a license deal to develop and commercialize one of the former's immunotherapeutic product candidates.Under the terms, HCW Biologics will receive a $7 million upfront payment from WY Biotech, while the latter will cover all expenses regarding research and development, manufacturing, clinical development, regulatory approval, and commercialization of the candidate, the companies added.HCW Biologics will cover costs for clinical development, regulatory approval, and commercialization of the candidate in the US, Canada, Central America, and Latin America, the parties said.HCW Biologics shares surged 246% in recent Monday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4139":"生物科技","BK4221":"木材房地产信托","BK4539":"次新股","HCWB":"HCW Biologics Inc.","BK4084":"特种房地产投资信托","WY":"惠好"},"translate_title":"HCW Biologics与怀俄明州Biotech签署免疫治疗候选产品许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCWB":1,"WY":1},"content_text":"HCW Biologics (HCWB) and WY Biotech said Monday they struck a license deal to develop and commercialize one of the former's immunotherapeutic product candidates.Under the terms, HCW Biologics will receive a $7 million upfront payment from WY Biotech, while the latter will cover all expenses regarding research and development, manufacturing, clinical development, regulatory approval, and commercialization of the candidate, the companies added.HCW Biologics will cover costs for clinical development, regulatory approval, and commercialization of the candidate in the US, Canada, Central America, and Latin America, the parties said.HCW Biologics shares surged 246% in recent Monday premarket activity.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Company Corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484362201"}